Meeting
2019 ASCO Annual Meeting
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
Authors
Mohammed M. Milhem
University of Iowa, Iowa City, IA
Mohammed M. Milhem , Georgina V. Long , Christopher J. Hoimes , Asim Amin , Christopher D. Lao , Robert Martin Conry , Jason Hunt , Gregory A. Daniels , Mohammed Almubarak , Montaser F. Shaheen , Theresa Michelle Medina , Minal A. Barve , Sarwan K. Bishnoi , Ehtesham A. Abdi , Michael Jon Chisamore , Biao Xing , Albert Candia , Erick Gamelin , Robert Janssen , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02521870
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9534)
DOI
10.1200/JCO.2019.37.15_suppl.9534
Abstract #
9534
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
First Author: Igor Puzanov
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2018 ASCO Annual Meeting
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.
First Author: Antoni Ribas
Poster
2016 ASCO Annual Meeting
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.
First Author: Adil Daud